Creon 10000 enteric capsules 150mg №10×2

Name:
Creon 10000 caps enteric solution 150mg in bl. in pack. 10х2
Description:
Two-color hard gelatin capsules (brown opaque cap and transparent colorless base). Capsule contents: Beige enteric-soluble mini-microspheres. The main active ingredient Pancreatin Release formCapsules 1 caps. pancreatin 150 mg amylase 8000 IU EF lipase 10000 IU EF protease 600 IU EF excipients: macrogol; liquid paraffin; methylhydroxypropyl cellulose phthalate; dimethicone 1000; dibutyl phthalate capsule shell: iron oxide red (E172); iron oxide black (E172); iron oxide yellow (E172); titanium dioxide (E171); gelatin Dosage 150mg in bl. in pack. 10×2 Special instructions In patients with cystic fibrosis who received high doses of pancreatin preparations, strictures of the ileum and caecum, colitis are described. In studies by the “case-control” method, no data were obtained indicating a relationship with Creon and the occurrence of fibrosing colonopathy. As a precautionary measure to rule out colonic involvement in patients with cystic fibrosis, it is recommended that any unusual symptoms or changes in the abdominal cavity be monitored, especially if the patient is taking more than 10,000 units of lipase/kg/day. The drug does not affect the ability to drive a car and to control machines and mechanisms. Pharmacological action Pharmacological action – replenishing the deficiency of pancreatic enzymes. Pharmacokinetics When the mini-microspheres reach the small intestine, the enteric coating breaks down, releasing enzymes with lipolytic, amylolytic, and proteolytic activities that promote the breakdown of fats, starches, and proteins. Indications for use: replacement therapy for exocrine pancreatic insufficiency in cystic fibrosis, chronic pancreatitis, pancreatectomy, pancreatic cancer, obstruction of the ducts (pancreatic ducts or common bile duct) due to neoplasm, Shwachman-Diamond syndrome, in old age; symptomatic therapy of digestive disorders with partial resection of the stomach (Billroth-I / II), total gastrectomy; after cholecystectomy, with duodeno- and gastrostasis, biliary obstruction, cholestatic hepatitis, cirrhosis of the liver, pathology of the terminal part of the small intestine, excessive bacterial growth in the small intestine. Dosage and administration Inside. The dose is selected individually depending on the severity of the disease and the composition of the diet. It is recommended to take 1/3 or 1/2 of a single dose at the beginning of a meal, the rest with a meal. When swallowing is difficult (for example, in young children or elderly patients), the capsules are carefully opened, and the mini-microspheres are added to liquid food that does not require chewing, or taken with liquid. Any mixture of Mini Microspheres with food or liquid should not be stored and should be taken immediately after preparation. Crushing or chewing mini-microspheres, as well as adding them to food with a pH above 5.5, leads to the destruction of their shell, which protects against the action of gastric juice. In cystic fibrosis, the dose depends on body weight and is at the beginning of treatment in children under 4 years old – 1000 lipase units / kg for each meal, over 4 years – 500 lipase units / kg during meals. The dose depends on the severity of the symptoms of the disease, the results of the control of steatorrhea and the maintenance of a good nutritional status. In most patients, the dose should not exceed 10,000 IU/kg/day. In other conditions accompanied by exocrine pancreatic insufficiency, the dose is set taking into account the individual characteristics of the patient (degree of indigestion, fat content in food). The dose with the main meal (breakfast, lunch and dinner) is 20,000-75,000 IU of lipase EF, while taking a light snack – 5,000-25,000 IU of lipase EF. The usual initial dosage of Creon® is 10,000-25,000 units of lipase EF with the main meal. To reduce steatorrhea and maintain the optimal condition of the patient, it is possible to increase the dose. According to the usual clinical practice, the patient should receive with food at least 20,000-50,000 units of lipase EF. Use during pregnancy and lactation In view of the lack of sufficient data on the safety of the use of pancreatic enzymes in women during pregnancy and lactation, the drug should be prescribed to pregnant women and breastfeeding mothers only if the expected benefit to the mother outweighs the possible risk to the fetus or child. Interaction with other drugs There are no reports of interaction with other drugs. ContraindicationsIncreased individual sensitivity to the components of the drug; acute pancreatitis; exacerbation of chronic pancreatitis. Composition textpancreatin 150 mg amylase 8000 IU EF lipase 10000 IU EF protease 600 IU EF excipients: macrogol; liquid paraffin; methylhydroxypropyl cellulose phthalate; dimethicone 1000; dibutyl phthalate capsule shell: iron oxide red (E172); iron oxide black (E172); iron oxide yellow (E172); titanium dioxide (E171); gelatin OverdoseSymptoms: hyperuricuria, hyperuricemia. Treatment: drug withdrawal, symptomatic therapy. Side effects Allergic reactions, rarely – diarrhea, constipation, discomfort in the stomach, nausea. Storage conditions At a temperature not higher than 20 °C. Keep out of the reach of children. Buy Creon 10000 enteric capsules 150mg No. 10×2 Price for Creon 10000 enteric capsules 150mg No. 10×2